| __timestamp | Amicus Therapeutics, Inc. | Jazz Pharmaceuticals plc |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 85181000 |
| Thursday, January 1, 2015 | 76943000 | 135253000 |
| Friday, January 1, 2016 | 104793000 | 162297000 |
| Sunday, January 1, 2017 | 149310000 | 198442000 |
| Monday, January 1, 2018 | 270902000 | 226616000 |
| Tuesday, January 1, 2019 | 286378000 | 299726000 |
| Wednesday, January 1, 2020 | 308443000 | 335375000 |
| Friday, January 1, 2021 | 272049000 | 505748000 |
| Saturday, January 1, 2022 | 276677000 | 590453000 |
| Sunday, January 1, 2023 | 152381000 | 849658000 |
Unleashing the power of data
In the dynamic world of biopharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Jazz Pharmaceuticals plc and Amicus Therapeutics, Inc. have demonstrated distinct strategies in their R&D allocations. From 2014 to 2023, Jazz Pharmaceuticals consistently increased its R&D investment, peaking in 2023 with a remarkable 850% growth from its 2014 levels. This strategic focus underscores Jazz's commitment to expanding its therapeutic portfolio.
Conversely, Amicus Therapeutics, while also increasing its R&D spending, showed a more fluctuating pattern, with a significant dip in 2023, reducing its R&D expenses by nearly 50% compared to the previous year. This variability may reflect strategic shifts or external challenges.
These insights highlight the contrasting approaches of two industry players, offering a window into their future trajectories and potential market impacts.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Amicus Therapeutics, Inc.
Research and Development Investment: BioMarin Pharmaceutical Inc. vs Jazz Pharmaceuticals plc
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Alpine Immune Sciences, Inc.
R&D Insights: How Jazz Pharmaceuticals plc and Ultragenyx Pharmaceutical Inc. Allocate Funds
Comparing Innovation Spending: Jazz Pharmaceuticals plc and MorphoSys AG
Research and Development Investment: Pharming Group N.V. vs Amicus Therapeutics, Inc.
R&D Insights: How Madrigal Pharmaceuticals, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: ADMA Biologics, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: ACADIA Pharmaceuticals Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Research and Development Investment: Amicus Therapeutics, Inc. vs Viridian Therapeutics, Inc.